Clinical Trials Logo

Genital Neoplasms, Female clinical trials

View clinical trials related to Genital Neoplasms, Female.

Filter by:

NCT ID: NCT02499952 Terminated - Ovarian Neoplasms Clinical Trials

Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors

Start date: January 2016
Phase: Phase 2
Study type: Interventional

This is an open label, multi-institutional, single arm phase II trial of pembrolizumab in patients with incurable platinum refractory germ cell tumors. No randomization or blinding is involved.

NCT ID: NCT02423876 Completed - Pain Clinical Trials

Epidural Anesthesia Within an Enhanced Recovery Pathway in Reducing Pain in Patients Undergoing Gynecologic Surgery

Start date: March 17, 2015
Phase: Phase 3
Study type: Interventional

This randomized clinical trial studies epidural anesthesia within an enhanced recovery pathway (ERP) in reducing pain in patients undergoing gynecologic surgery. An epidural analgesia (pain relief) is a small tube placed in the lower back that numbs the nerves and stops the feeling of pain. It stays in place for several days after surgery and may be helpful for pain control in patients with gynecologic cancer after surgery. ERP is a set of specific steps used before, during, and after surgery by health care providers to care for patients after surgery. ERPs include patient education, not using laxatives before surgery, increasing activity after surgery, and scheduled use of medications for pain and nausea. Giving epidural anesthesia as part of an ERP may improve pain control in patients undergoing gynecologic surgery.

NCT ID: NCT02408406 Active, not recruiting - Breast Carcinoma Clinical Trials

PatientCareAnywhere Internet-Based Software in Improving Communication and Education in Patients With Cancer and Their Healthcare Providers

Start date: July 7, 2015
Phase: N/A
Study type: Interventional

This partially randomized pilot clinical trial develops and studies a software program, called PatientCareAnywhere, to see whether it can help patients communicate with their doctors and other healthcare providers, and educate themselves about their cancer and treatment options. A program that can help patients learn about their cancer and treatment options, and allows the patient's healthcare providers to receive their questionnaire results, may help patients identify and get help to treat their symptoms.

NCT ID: NCT02315469 Completed - Clinical trials for Primary Peritoneal Carcinoma

Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery

Start date: February 10, 2015
Phase:
Study type: Observational

This research trial studies comprehensive patient questionnaires in predicting complications in older patients with gynecologic cancer undergoing surgery. Comprehensive patient questionnaires completed before surgery may help identify complications, such as the need for assistance in taking medications, decreased mobility, decreased social activity, and falls, and may improve outcomes for older patients with gynecologic cancer.

NCT ID: NCT02309944 Completed - Obesity Clinical Trials

Negative Pressure Wound Therapy in Obese Gynecologic Oncology Patients

Start date: May 2015
Phase: N/A
Study type: Interventional

The purpose of the study is to test whether the use of a new wound closure technique can decrease the rates of wound complications in obese cancer patients.

NCT ID: NCT02192333 Completed - Depression Clinical Trials

Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors

Start date: August 3, 2015
Phase: N/A
Study type: Interventional

This randomized clinical trial studies survivorship care in reducing symptoms in young adult cancer survivors. Survivorship care programs that identify the needs of young adult cancer survivors and ways to support them through the years after treatment may help reduce symptoms, such as pain, fatigue, sleep disturbance, depression, and distress, in young adult cancer survivors.

NCT ID: NCT02182245 Completed - Clinical trials for Genital Neoplasms, Female

Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies

Start date: October 2005
Phase: Phase 1
Study type: Interventional

The primary objectives of this trial were to determine the safety, tolerability, and MTD of BIBF 1120 when added to standard therapy with carboplatin and paclitaxel

NCT ID: NCT02020707 Active, not recruiting - Clinical trials for Malignant Solid Neoplasm

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

Start date: February 24, 2014
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of nab-paclitaxel and bevacizumab in treating patients with stage IV melanoma that cannot be removed by surgery (unresectable), cancer of the cervix, endometrium, ovary, fallopian tube or peritoneal cavity. Drugs used in chemotherapy, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab may stop or slow tumor growth by blocking the growth of new blood vessels necessary for tumor growth. Giving nab paclitaxel and bevacizumab may kill more tumor cells than nab-paclitaxel alone.

NCT ID: NCT01871688 Recruiting - Clinical trials for Malignant Female Reproductive System Neoplasm

Pelvic Floor Rehabilitation for Gynecological Cancer Patients

Start date: April 2013
Phase: Phase 2/Phase 3
Study type: Interventional

As cancer treatment improves, the cancer survivor's quality of life and level of function have gained increasing importance. Pelvic floor function is directly affected by gynecological cancer and treatment, and pelvic floor dysfunction (PFD) can severely affect a patient's life. PFD negatively affects health-related quality of life (HRQOL). Evaluation of PFD provides information about the disease burden and treatment-related effects directly from the patient's perspective and informs clinical decision-making. The pelvic floor musculature and sacral nerves are not easily accessible, and it is difficult to test them. Several functional assessments have been used to evaluate pelvic floor dysfunction; however, reports on methodology are sparse, and consensus on their use is lacking. Research on functional outcomes is highly complex and, consequently, must be addressed in a comprehensive framework.

NCT ID: NCT01784406 Completed - Survivorship Clinical Trials

Person-centred Support for Women After Treatment for Gynaecological Cancer

PESU
Start date: January 2013
Phase: N/A
Study type: Interventional

Women treated for gynaecological cancer perceive many difficulties in life on the personal, social, and physical levels. Today they are offered a 3 to 5 year follow-up programme at the hospital where the main purpose is to improve survival. However, the women are very nervous before follow-up visits and although they feel safe about them, they express that their needs of psychosocial care and self-management support are not fulfilled. The proposed study will test a person-centred intervention tailored the women's needs in a randomised controlled trial. The intervention will be based on the method Guided Self Determination (GSD), which has proved able to realize empowerment in practice in relationships between patients and healthcare professionals. GSD involves systematic use of condition-adjusted worksheets ('reflection sheets'), and advanced professional communication. Using reflection sheets filled out by each woman as the starting point for communication, problem solving will be tailored her personal needs. We expect that the intervention has the potential to support the women in better managing specific complications and difficulties related to concerns about recovery, body perception, fertility and establishment of intimate relations with their partner, all aspects important for the women's quality of life in the follow-up period after cancer diagnosis and treatment. The study will be the first to test GSD in cancer patients.